Author:
Hino Masayuki,Matsumura Itaru,Fujisawa Shin,Ishizawa Kenichi,Ono Takaaki,Sakaida Emiko,Sekiguchi Naohiro,Tanetsugu Yusuke,Fukuhara Kei,Ohkura Masayuki,Koide Yuichiro,Takahashi Naoto
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Pfizer Inc. Bosulif® (bosutinib) prescribing information. 2012 (last update: Dec 2017). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203341s009lbl.pdf. Accessed 11 Nov 2019.
2. European Medicines Agency. Bosulif® (bosutinib) summary of product characteristics. 2013 (last update: Aug 7, 2019). https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif. Accessed 11 Nov 2019.
3. Pfizer Japan Inc. Bosulif® (bosutinib hydrate) prescribing information. Japan; 2017.
4. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–7.
5. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567–76.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献